Complete interferon--receptor-1 deficiency (IFN R1) is a primary immunodeficiency disease characterized by high susceptibility to recurrent, severe mycobacterial and other intracellular infections. We here report the first successful treatment of the disorder by bone marrow transplantation (BMT). The 8 year old girl had suffered from recurrent mycobacterial infections in the past and had developed liver cirrhosis with portal hypertension. For conditioning, fractionated total body irradiation (TBI) was used in combination with cyclophosphamide and ATG. The patient was transplanted with red cell depleted bone marrow from her HLA-identical sister. The transplant course was uneventful and 4 years later, the child remains in excellent clinical condition and free of mycobacterial infections. She has stable mixed lympho-hematopoetic chimerism after repeat T-cell transfusions. Liver disease has not further deteriorated. This experience shows that correction of IFN R1 deficiency is possible by BMT and complications of the disease can be controlled .
Introduction
Complete interferon--receptor-1 deficiency (IFN R1) is an autosomal recessively inherited disorder 1 , which has a very poor prognosis due to severe complications from infections caused in particular by mycobacteriae and other intracellular microorganisms like Listeria monocytogenes and Salmonella species 2 3 4 5 . In 1996 Newport et al. 6 identified the gene for INF R1 on chromosome 6 (q16-22). Mutations in this gene may lead to a lack of expression or function of IFN R1. In macrophages this results in a failure to become activated upon exposure to IFN-, leading to lack of TNF--production and profound deficiency in intracellular killing of pathogens 6 . To date, complete IFN R1 deficiency has been identified in nine kindreds (17 patients). Mutations in these patients included nonsense and splice mutations as well as frameshift deletions and insertions. These mutations were located in the segment encoding the extracellular domain of the receptor 7 . The resulting premature stop 
Case report
The patient was born as the second child of healthy, unrelated parents. There was no family granulomatous disease were excluded. In 1997 (at the age of 7 years), complete INFyR1 deficiency was diagnosed as described elsewhere 4 . Seven months later, in October 1997, the patient was transferred to our center for BMT.
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Findings before BMT
On admission, the patient was in stable clinical condition with body length and weight at the 25th percentile. She was on antibiotic prophylaxis with Ciprofloxacin. There was no evidence of active mycobacterial infection. The abdomen was distended with marked hepatosplenomegaly (liver length 14 cm, spleen length 17 cm). Liver function was impaired with decreased synthesis of cholinesterases. Computerized abdominal tomography showed signs of liver cirrhosis and of portal hypertension with collateral circulation. Apart from mild icterus, the skin was without any abnormalities. Other organ functions, in particular pulmonary functions, were normal.
Treatment by BMT
BMT was performed after obtaining written consent from both parents. Conditioning consisted of TBI applied in 6 fractions at 2 Gy over 3 days (cumulative dosis 12 Gy) with complete shielding of the lungs, followed by cyclophosphamide at 60 mg/kg/day i.v. in one daily dose on two days (total dose 120 mg/kg) and antithymocyte globulin (ATG, Merieux) at 10mg/kg/day daily for three days (total dose 30 mg/kg). Bone marrow from the HLAidentical 12-year old sister was infused, following depletion of red cells from the graft because of blood group incompatibility. The number of nucleated cells was 3,87 x 10 8 /kg.
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Results and Discussion
Hematological reconstitution was characterized by appearance of leukocytes on day +18 after BMT. Granulocyte-colony-stimulating factor (G-CSF) at 5 µg/kg/day was used from day +18 until day +24. Reticulocytes >20‰ were reached on day +35 and platelet transfusions were required until day +71. GvHD prophylaxis consisted of anti-interleukin-II-receptor-antibodies (Leukotac, Biotest) at a dose of 0,2 mg/kg/day from day 0 until day +17, and at 0,1 mg/kg/day from day +18 until day +39. On day +9, cyclosporine A was started at a dose of 2 mg/kg/day and was continued until day +57. The patient remained free of infections and of complications from GvHD and there was no evidence of liver toxicity. Antimycobacterial prophylaxis was discontinued at 6 weeks after BMT. At 4 months after BMT, the blood group was >80% donor type, and molecular studies, performed 9 months after BMT, revealed normal 
org From
She remains in excellent clinical condition more than 4 years after BMT (Karnofsky-index 100%).
INFyR1 deficiency in the patient was complicated by advanced liver disease presumably caused by the recurrent atypical mycobacterial infections. This complication had deteriorated to a point where liver transplantation was taken into consideration, which however was postponed until successful reconstitution after BMT. In the conditioning regimen the use of busulfan was avoided, which is known for its liver toxicity, and TBI was used instead. In addition, the use of cyclosporine A, another hepatotoxic drug, was avoided during the early phase after BMT. Following BMT, liver functions did not deteriorate furtherand in fact, the hepatic disease in the patient has remainedstable until now .. 
